Teva Pharmaceutical Industries Ltd. (TEVA)

16.91
0.27 1.62
NYSE : Health Technology
Prev Close 16.64
Open 16.75
Day Low/High 16.69 / 17.05
52 Wk Low/High 14.59 / 25.96
Volume 7.02M
Avg Volume 11.16M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 18.20B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Announces Launch Of An Authorized Generic Of Flector® Patch (diclofenac Epolamine Topical Patch) In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of an authorized generic of Flector ®1 Patch, 1.

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission

Teva Pharmaceuticals shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals.

Teva Finalizes Settlement With Federal Trade Commission To Resolve All Outstanding Litigation Between The Parties

Teva Finalizes Settlement With Federal Trade Commission To Resolve All Outstanding Litigation Between The Parties

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a settlement with the Federal Trade Commission (FTC) that will resolve all outstanding litigation between the parties.

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva Pharmaceuticals CEO Talks "Trough Year", 2020 Turnaround

Teva's CEO explains why 2019 is a trough year for the Israeli pharma company.

3 Things to Know at Market Close: Teva, Google and Cisco

3 Things to Know at Market Close: Teva, Google and Cisco

Here's what you need to know on TheStreet.

Teva Pharma Tumbles as Earnings and Outlook Miss Estimates

Teva Pharma Tumbles as Earnings and Outlook Miss Estimates

Teva posts a fourth-quarter earnings miss and issues lower-than-expected guidance for 2019.

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon

China trade discussions will continue to be a key driver in Wednesday's market action.

Teva Reports Fourth Quarter And Full Year 2018 Financial Results

Teva Reports Fourth Quarter And Full Year 2018 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2018.

Teva Announces U.S. Launch Of A Generic Version Of Sabril® (Vigabatrin)

Teva Announces U.S. Launch Of A Generic Version Of Sabril® (Vigabatrin)

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Sabril ®1 (vigabatrin) tablets, 500 mg in the US, the first generic version of Sabril ® (vigabatrin) tablets to enter the US market.

Teva Announces Launch Of ALYQ™ (Tadalafil Tablets USP), A Generic Version Of ADCIRCA® In The United States

Teva Announces Launch Of ALYQ™ (Tadalafil Tablets USP), A Generic Version Of ADCIRCA® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of ALYQ™, a generic version of ADCIRCA ®1 (tadalafil) tablets, 20 mg in the U.

Teva Receives Positive Committee For Medicinal Products For Human Use (CHMP) Opinion For AJOVY® (fremanezumab) For The Prophylaxis Of Migraine In Adults

Teva Receives Positive Committee For Medicinal Products For Human Use (CHMP) Opinion For AJOVY® (fremanezumab) For The Prophylaxis Of Migraine In Adults

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for AJOVY ® (fremanezumab)...

Weakness From CAT and NVDA Support Our Repositioning Efforts

The big week of corporate earnings is upon us.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2018 Financial Results At 8 A.m. ET On February 13, 2019

Teva To Host Conference Call To Discuss Fourth Quarter And Full Year 2018 Financial Results At 8 A.m. ET On February 13, 2019

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2018 financial results on Wednesday, February 13, 2019 at 7:00 a.

Teva To Present At The 37th Annual J.P. Morgan Healthcare Conference

Teva To Present At The 37th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced that members of management will present at the 37th Annual J.

Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product

Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced today that it has resolved its ongoing dispute with Amgen over Teva's generic cinacalcet HCl product.

Teva Announces FDA Approval Of First And Only Digital Inhaler With Built-In Sensors - ProAir® Digihaler™ (albuterol Sulfate 117 Mcg) Inhalation Powder

Teva Announces FDA Approval Of First And Only Digital Inhaler With Built-In Sensors - ProAir® Digihaler™ (albuterol Sulfate 117 Mcg) Inhalation Powder

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

I See No Technical Reason to Approach Teva Pharmaceuticals From the Long Side

Jim Cramer was bearish on TEVA.

Teva, CyberArk, Ford: 'Mad Money' Lightning Round

Teva, CyberArk, Ford: 'Mad Money' Lightning Round

Jim Cramer weighs in on Teva, CyberArk and Ford.

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Buying stocks now means you are in the uncomfortable position of fighting the Fed as it tries to slow the economy.

Teva Announces Positive Topline Phase IIIb Results With Fremanezumab In Adults With Migraine Who Did Not Respond To Multiple Classes Of Preventive Treatments

Teva Announces Positive Topline Phase IIIb Results With Fremanezumab In Adults With Migraine Who Did Not Respond To Multiple Classes Of Preventive Treatments

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from the Phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who...

Teva's Generic Version Of EpiPen® (Epinephrine Injection, USP) Auto-Injector 0.3 Mg Now Available In Limited Quantity In The United States

Teva's Generic Version Of EpiPen® (Epinephrine Injection, USP) Auto-Injector 0.3 Mg Now Available In Limited Quantity In The United States

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen ®1 (epinephrine injection, USP) Auto-Injector, 0.

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'

Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Fab Five FAANG Stocks: Cramer's 'Mad Money' Recap (Tuesday 11/13/18)

Jim Cramer's got a different perspective on the recent performance of the companies we love to hate: Facebook, Amazon, Apple, Netflix, Google.

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Dropbox, Teva Pharmaceuticals, Salesforce: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Dropbox, Teva Pharmaceuticals, Salesforce, Linde, iQiyi and more.

TheStreet Quant Rating: D (Sell)